ARID1A and neuroendocrine carcinoma: Best survival rates were seen in the NEC-like SMARCA4/ARID1A group, although there was no significant difference in comparison with the other two classes (vs. ACC: p = 0.163; vs. NEC-like IDH2: p = 0.168).